

Prezentační aktivity Kliniky hematologie v zahraničí - výběr

1 – 12/ 2022

11/2022

- **Hájek R.** RWE: modern triplets in RRMM, **Multiple Myeloma and Related Malignancies” – Sixth Edition**, Italy, 11/2022
- **Hájek R.** The experience in the Czech Republic, **Assessing Barriers to Access in Clinical Trials in CEE Countries**, on-line, 11/2022

8/2022

- **Hájek R.** Real-World Outcomes in RRMM: The Feasibility of All-Oral Triplet Therapy with Ird, **Speaker Tour**, Colombia, 8/2022
- **Hájek R.** Chair of the Abstract session 4, **19th International Myeloma Society Annual Meeting**, USA, 8/2022

5/2022

- **Hájek R.** The new normal? Looking beyond the COVID-19 era in your clinical practice, **COMy 2022 Symposium with Takeda It's MMy Life: Your specialty, my world**, France, 5/2022
- **Hájek R.** Participant in the discussion panel: „Treatment of multiple myeloma across Europe”, **4th International Conference on Clinical and Experimental Hematology**, Poland, 5/2022
- **Hájek R.** Quick Reflection of Fast Progress in Multiple Myeloma Treatment, **IX. MISKOLCI MYELOMA KONFERENCIA**, Hungary, 5/2022
- **Hájek R.** Quick Reflection of Fast Progress in Multiple Myeloma Treatment, **Myelómová akadémia 2022**, Slovak Republic, 5/2022
- **Hájek R.** Chair of the session “Liečba relabovaného/refraktérneho myelómu“, **Myelómová akadémia 2022**, Slovak Republic, 5/2022

4/2022

- **Hájek R.** Future diagnostic approach and how do I treat myeloma in Czech Republic? **11th Conference of Current & Future Perspectives of MM Treatment**, Poland, 4/2022
- **Hájek R.** Chair of the “SESSION VIII: NEWLY DIAGNOSED MM”, **3rd European Myeloma Network Meeting**, on-line, 4/2022

3/2022

- **Hájek R.** Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. **Symposia Oncoclinicas**, on-line, Brasilia, 3/2022

- **Hájek R.** Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. **EBMT 2022 Annual Meeting**, hybrid, 3/2022.
- **Hájek R.** Management of myeloma relapse after HSCT. **EBMT 2022 Annual Meeting**, hybrid, 3/2022.

1 – 12/ 2021

12/2021

- **Jelínek T.** Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia. **American Society of Hematology – 63rd Annual Meeting, Atlanta, USA, December 2021.**

11/2021 – on line přednášky

- **Hájek R.** Real world evidence versus clinical trials. Treatment decisions based on this data. **Meet the Expert – dr. Roman Hajek**, on-line, Argentina, 11/2021
- **Hájek R.** Experience on the development and implementation of national registry for Multiple Myeloma in Czech Republic. **Meet the Expert – dr. Roman Hajek**, on-line, Argentina, 11/2021

10/2021 – Slovensko

- **Hájek R.** Quick Reflection of Fast Progress in Multiple Myeloma Treatment. **X. Bratislavské hematologické a transfúziologické dni**, Bratislava, Slovak Republic, 10/2021

10/2021 – on line přednášky

- **Hájek R.** Clinical benefit of the triplet Ixazomib+Rd in the real-world clinical practice. **IXprActice: sharing international and local experiences, Italy, on-line, 10/2021**

9-10/2021 – on line přednášky

- **Hájek R.** Real-World Outcomes in RRMM: The Feasibility of All-Oral Triplet Therapy with IRd. **Meeting with the expert – Speaker Tour: RWE IRd**, on-line, Colombia, 9-10/2021

9/2021 – Rakousko

- **Hájek R.** Allo-CAR-T cells. **IMW**, Austria, 9/2021
- **Hájek R.** Allogeneic CAR-T cell therapy. **IMW**, Austria, 9/2021

7/2021 – on line přednášky

- **Hájek R.** A Clinical Perspective on Access in Central and Eastern European and Balkan Countries. **MPE Masterclass**, on-line, 7/2021

6/2021 – on line přednášky

- **Hájek R.** Unmet Medical Needs and Current Treatment Guidelines. **Zhongshan Myeloma Summit**, China, on-line, 6/2021
- **Hájek R.** Real-world outcomes in RRMM. **Onco Virtual Summit**, Corea, on-line, 6/2021

- **Hájek R.** Optimal treatment strategy for RRMM patients including high risk and biochemical relapse. **Onco Virtual Summit**, Corea, on-line, 6/2021
- **Hájek R.** Real-World Outcomes in RRMM: The Feasibility of All-Oral Triplet Therapy with Ird. **EHA Takeda MM Satellite Symposium**, on-line, 6/2021

5/2021 – on line přednášky

- **Hájek R.** Real world outcomes in RRMM: bridging the gap. **COMy Takeda symposium**, on-line, 5/2021

4/2021 on line přednášky

- **Hájek R.** Chairman of the Session VI: German Study Groups – Quo Vadis? **8TH HEIDELBERG MYELOMA WORKSHOP**. Germany, on-line, 4/2021

3/2021 – on line přednášky

- **Hájek R.** Switch induction or go directly to transplant in case of suboptimal response? (switch induction). **2nd European Myeloma Network meeting**, on-line, 3/2021
- **Hájek R.** Clinical benefit of the triplet Ixazomib+Rd in the real world clinical practice. **IXprActice: sharing international and local experiences**, Italy, on-line, 3/2021

1/2021 – on line přednášky

- **Hájek R.** Real World Outcomes and Factors Impacting Treatment Choice In Relapsed And/Or Refractory Multiple Myeloma (RRMM). **Takeda Hema symposium**, Taiwan, on-line, 1/2021

1 – 12/ 2020

11/2020 – on line přednášky

- **Hájek R.** Choosing the Right Treatment Pathway for Your R/R MM. **MM summit “Hope & Extended Possibilities”**, Saudi Arabia, on-line, 11/2020
- **Hájek R.** New guidelines in managing MM patients in light of COVID-19. **MM summit “Hope & Extended Possibilities”**, Saudi Arabia, on-line, 11/2020
- **Hájek R.** Key factors affecting treatment decision – making in the real word setting. **MM summit “Hope & Extended Possibilities”**, Saudi Arabia, on-line, 11/2020
- **Hájek R.** An Importance of Real Word Evidence (RWE) in Multiple Myeloma. **MULTIPLE MYELOMA and related malignancies 5th Edition 2020 Webinar**, Bari, on-line, 11/2020

10/2020 – on line přednášky

- **Hájek R.** Management mnohočetného myelomu v roce 2020 se zaměřením na léčbu nemocných refrakterních na lenalidomid. **Banskobystrické hematologické a transfúziologické dni**, on-line, 10/2020
- **Hájek R.** Emerging Data of PIs in RRMM: Focus on Lenalidomide Exposed/Refractory Patients. **MM expert forum**, on-line, 10/2020
- **Hájek R.** What to do in lenalidomide refractory MM patients? **MM expert forum**, on-line, 10/2020
- **Hájek R.** Closing the Efficacy and Effectiveness Gap: Ixazomib-Lenalidomide-Dexamethasone in RRMM patients in Routine Clinical Practice. **Lymphotuesday Virtual Forum of Experts in diagnostics and treatment of multiple myeloma**, Russia, on-line, 10/2020

- **Hájek R.** Case report - elderly RRMM. **Lymphotuesday Virtual Forum of Experts in diagnostics and treatment of multiple myeloma**, Russia, on-line, 10/2020
- **Hájek R.** Real World Experience in Relapsed/Refractory Multiple Myeloma. **Takeda's symposium „Real world experience in relapsed refractory Multiple Myeloma“**, Saudi Arabia, on-line, 10/2020
- **Hájek R.** Current therapy of AL amyloidosis and potential impact of ANDROMEDA trial: perspective from Czech Republic. **4th Interdisciplinary Conference „Amyloidoza“**, Poland, on-line, 10/2020

8/2020 – on line přednášky

- **Hájek R.** RWE and Treatment Considerations on RRMM. **EMERGE event**, Brasilia, on-line, 7/2020

7/2020 – on line přednášky

- **Hájek R.** Optimizing Treatment Strategies in Relapsed/ Refractory Multiple Myeloma. **Multiple Myeloma Onco-Summit**, Korea, on-line, 7/2020
- **Hájek R.** Holistic review of Real-world experience in Multiple Myeloma. **Multiple Myeloma Onco-Summit**, Korea, on-line, 7/2020

5/2020 – on line přednášky

- **Hájek R.** The European Myeloma Network. **6th COMy 2020**, on-line, 5/2020

3/2020 – on line přednášky

- **Hájek R.** Clinical consideration at first relapse. **Janssen Hematology Academy_2020**, on-line, 3/2020

2/2020 Polsko

- **Hájek R.** Elderly MM Patients – optimal choice of therapy. **10. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, 2/2020

1 – 12/ 2019

10/2019 Singapur

- **Hájek R.** Real-world considerations in the treatment of RRMM. **Singapore and EM speaker tour**. Singapur, 10/2019

9/2019 USA

- **Hájek R.** Management of Challenging Cases. **17th International Myeloma Workshop**. Boston, 9/2019
- **Hájek R.** Co-chair Session: Antibody Based Approaches to MM. **17th International Myeloma Workshop**. Boston, 9/2019

7/2019 Čína

- **Hájek R.** MM Real-World Data vs clinical trial. **Myeloma Real-World Data International Speaker Tour**. Shanghai, Tianjin, Jinan, 7/2019

5/2019 Francie

- **Hájek R.** The European Myeloma Network. **5th World Congress on Controversies in Multiple Myeloma**. Paříž, 5/2019

- **Hájek R.** chair Session 11: Options for refractory myeloma. **5th World Congress on Controversies in Multiple Myeloma.** Paříž, 5/2019

5/2019 Maďarsko

- **Hájek R.** Czech registry and utilization in clinical practice and health economic modeling. **MM Expert Panel.** Budapešť, 5/2019
- **Hájek R.** Positioning of proteasome inhibitors in current ESMO Guidelines. **MM Expert Panel.** Budapešť, 5/2019

4/2019 Rakousko

- **Hájek R.** Unmet medical need in RRMM treatment. **Oncology Summit.** Vídeň, 4/2019

4/2019 Saudská Arábie

- **Hájek R.** Multiple myeloma post SCT maintenance. **9th Annual SSBMT/EBMT 2019 Highlights congress.** Jeddah, 4/2019

4/2019 Německo

- **Hájek R.** Emerging Drugs and Targets. **7TH HEIDELBERG MYELOMA WORKSHOP.** Heidelberg, 4/2019

3/2019 Švýcarsko

- **Hájek R.** Real World Evidence in Multiple Myeloma. **Relapsed Refractory Multiple Myeloma AB,** Zurrich, 3/2019

3/2019 Polsko

- **Hájek R.** How I treat multiple myeloma in Central and Eastern Europe (CEE) using the newest drugs. **9th Current & Future Perspectives of MM Treatment and Other Hematological Malignancies Treatment Conference,** Varšava, 3/2019

2/2019 Portugalsko

- **Hájek R.** Translating Clinical Trial Results into Real-world Solutions. **2nd Annual Global Summit on Hematologic Malignancies,** Lisbon, 2/2019

1 – 12/ 2018

11/2018 Rusko

- **Hájek R.** Multiple Myeloma - A Quick Reflection on the Fast Progress. **Scientific Symposium "Paraproteinemic hemoblastosis",** Novosibirsk, 11/2018

11/2018 Rumunsko

- **Hájek R.** Registry of monoclonal gammopathies (RMG). **NEE Multiple Myeloma Expert Forum,** Bucharest, 11/2018
- **Hájek R.** Practical aspects of MM treatment – sequencing, duration or treatment. **NEE Multiple Myeloma Expert Forum,** Bucharest, 11/2018

10/2018 Slovenská republika

- **Hájek R.** Multiple Myeloma - A Quick Reflection on the Fast Progress. **IX. Bratislavské hematologické a transfúziologické dny**, Bratislava, 10/2018

9/2018 Belgie

- **Hájek R.** Considering patient centricity when emerging therapies are booming in MM. Factors influencing therapeutic decisions. **KOL tour Belgium**, Brussels, 9/2018

6/2018 Švédsko

- **Hájek R.** Chair of the EHA-ISLH Laboratory Diagnosis Workshop Symposium on “MRD diagnostics in multiple myeloma trials”. **23rd Congress of the European Hematology Association (EHA)**, Stockholm, Sweden, 6/2018

6/2018 Polsko

- **Hájek R.** CEE experience in advancing new technologies to MM patients. **CEE Health Innovation Forum**, Warsaw, Poland, 6/2018

5/2018 Polsko

- **Hájek R.** The role of autologous transplantation in multiple myeloma. Conference „**Progress in transplantology, haematology and cell therapies**”, Szczecin, Poland, 5/2018

5/2018 Slovensko

- **Hájek R.** LÉČEBNÁ STRATEGIE MNOHOČETNÉHO MYELOMU & GUIDELINES 2018. **Myelómové fórum 2018**, Bratislava, Slovak Republic, 5/2018

5/2018 Polsko

- **Hájek R.** Multiple Myeloma - A Quick Reflection on the Fast Progress. **III International Conference on Clinical and Experimental Hematology**, Kazimierz Dolny, Poland, 5/2018

3/2018 Chorvatsko

- **Hájek R.** Multiple myeloma-best practices from Czech Republic. **educational event Treatment of lymphoproliferative diseases an update**, Trakošćan, Croatia, 3/2018

3/2018 Rumunsko

- **Hájek R.** The role of minimal residual disease in MM in 2018. **Hematology Chronic Dialogues**, Cluj-Napoca, Romania, 3/2018
- **Hájek R.** Practical management of daratumumab in patients with MM in Czech Republic. **Hematology Chronic Dialogues**, Cluj-Napoca, Romania, 3/2018

2/2018 Polsko

- **Hájek R.** Immunomodulation & Immunotherapy in MM. **8. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, 2/2018

1 – 12/ 201711/2017 Rakousko

- **Hájek R.** Guideline overview, recent changes, and implications for Central Eastern Europe. **Multiple Myeloma Expert Forum Meeting**, Vienna, Austria, 11/2017

10/2017 Polsko

- **Hájek R.** Treatment of plasma cell myeloma. State of the art. **Conference on Progress in oncology**, Gliwice, Poland, 10/2017
- **Hájek R.** Chairman of the Bone marrow transplantology session. **Conference on Progress in oncology**, Gliwice, Poland, 10/2017

9/2017 Česká republika

- **Hájek R.** Relapsed and/or Refractory Multiple Myeloma treatment landscape across North East Europe. **MM Expert Panel Meeting**, Prague, Czech Republic, 9/2017
- **Hájek R.** MGUS & Smoldering Myeloma. How to predict outcome & “To treat or not to treat”. **IMS Educational Workshop**, Prague, Czech Republic, 9/2017
- **Hájek R.** Co-Chair of the workshop. **IMS Educational Workshop**, Prague, Czech Republic, 9/2017

9/2017 Polsko

- **Hájek R.** Novel diagnostic methods in multiple myeloma. When should we start the treatment? **27th Congress of the Polish Society of Hematology and Transfusion Medicine**, Warsaw, Poland, 9/2017

7/2017 Švýcarsko

- **Hájek R.** 3. Response in an elderly, comorbid RRMM patient ineligible for ASCT, **Multiple Myeloma (MM) European Advisory Board**, Zurich, Switzerland, 7/2017

6/2017 Španělsko

- **Hájek R.** Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). **22st Congress of the European Hematology Association (EHA)**, Madrid, Spain, 6/2017

5/2017 Německo

- **Hájek R.** Single vs. double transplantation. **6th Heidelberg Myeloma Workshop**, Heidelberg, Germany, 5/2017

4/2017 Polsko

- **Hájek R.** Multiple myeloma therapy – beyond 2017. **Conference „Hematology – how to treat ...in 2017”**, Wroclaw, Poland, 4/2017

4/2017 Slovensko

- **Hájek R.** Current and future treatment options for Multiple Myeloma, focus to relaps/ refractory. **Ninlaro Deep Dive Medical Training**, Bratislava, Slovak Republic, 4/2017

3/2017 Indie

- **Hájek R.** Oral session chair - Session 2: Novel Drug Targets. **16th International Myeloma Workshop**, New Delhi, India, 3/2017

2/2017 Polsko

- **Hájek R.** Transplant Not-eligible Patients. **7. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, 2/2017

1 – 12/ 201610/2016 Slovensko

- **Hájek R.** Léčebný pokrok u relabujícího mnohočetného myelomu. **VIII. Bratislavské hematologické a transfuziologické dni.** Bratislava, Slovak Republic, 10/2016

9/2016 Finsko

- **Hájek R.** Triplet Therapies for Relapsed Multiple Myeloma and the Role of Cytogenetic Testing and Risk Assessment in Treatment Selection. **Annual intensive day meeting for Finnish haematologists, 'Intensive day warm-up'**, Helsinki, Finland, 9/2016,

7/2016 Rakousko

- **Hájek R.** Pro & Contra-Session: „Good bye to CRAB - should we treat MM earlier ?“ and how**FIRST AUSTRIAN MYELOMA SUMMER SCHOOL 2016.** Salzburg, Austria, 7/2016

6/2016 Jihoafrická republika

- **Hájek R.** Toward the Cure - Multiple Myeloma. **4th African Pharma Congress.** Cape Town, South Africa, 6/2016

6/2016 Dánsko

- **Hájek R.** - chair of the Education Session on “Multiple myeloma. 21st Congress of the European Hematology Association (**EHA**). Copenhagen, Denmark, 6/2016.

5/2016 Polsko

- **Hájek R.** Do we still need alkylators in the era of IMiD's and PI's? **II Międzynarodowa Konferencja Szkoleniowa "Hematologia Kliniczna i Doświadczalna"**, Kazimierz Dolny, Poland, 5/2016

5/2016 Slovensko

- **Gumulec J.** Heparinem indukovaná trombocytopenie. **XXIII.Slovensko-česká konferencia o hemostáze a trombóze.** Martin, Slovak Republic. 5/2016
- **Hájek R.** Současný význam Minimal Residual Disease u mnohočetného myelomu. **Myelomové fórum 2016**, Bratislava, Slovak Republic, 5/2016
- **Kaščák M.** Raritní diagnózy v hematologii. Amyloidóza a Waldenströmova makroglobulinemie, **Myelomové fórum 2016**, Bratislava, Slovak Republic 5/016

4/2016 Slovinsko

- **Hájek R.** The new therapies and challenges in treating Multiple Myeloma. **5th CONGRESS OF SLOVENIAN HAEMATOLOGICAL SOCIETY.** Laško, Slovenia. 4/2016

2/2016 Polsko

- **Hájek R.** Pathophysiology of MM and targets for existing & future drugs and their Combinations. **6. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, 2/2016

1/2016 Polsko

- **Hájek R.** Sequential treatment and modern therapies for Multiple Myeloma. **Haematologic Workshop**, Szczecin, Poland 1/2016

1 – 12/ 201512/2015 USA

- Wee-Joo Chng, H. Goldschmidt, M.A. Dimopoulos, P. Moreau, D. Joshua, A. Palumbo, T. Facon, H. Ludwig, L. Pour, R. Niesvizky, A. Oriol, L. Rosiñol, A. Suvorov, G. Gaidano, T. Pika, K. Weisel, V. Goranova-Marinova, H. Gillenwater, N. Mohamed, S. Feng, **R. Hájek**. Efficacy and Safety of Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis From the Phase 3 Study ENDEAVOR (NCT01568866). **American Society of Hematology - 57th Annual Meeting**, Orlando, USA, December 2015.
- P. Moreau, D. Joshua, Wee-Joo Chng, A. Palumbo, H. Goldschmidt, **R. Hájek**, et al. Impact of Prior Treatment on Patients With Relapsed Multiple Myeloma Treated With Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 ENDEAVOR Study (NCT01568866). **American Society of Hematology - 57th Annual Meeting**, Orlando, USA, December 2015.

9/2015 Itálie

- **Hájek R.** Ongoing Studies/Open Questions in Europe. **15th International Myeloma Workshop**. Roma, Italy, September 2015.

9/2015 Slovenská republika

- **Hájek R.** Kam kráčíš, myelome? Léčebné strategie současnosti. **XVII. Slovensko český hematologický a transfuziologický zjazd**. Bratislava, The Slovak Republic, September 2015.
- **Kaščák M., Hájek R.** Novinky v diagnostice a léčbě Waldenströmovy makroglobulinémie, **XVII. Slovensko český hematologický a transfuziologický zjazd**. Bratislava, The Slovak Republic, September 2015.
- **Tóthová E.** Výskyt a manažment nežiaducich účinkov inhibítorov tyrozínkinázy počas liečby chronickej myelocytovej leukémie. **XVII. Slovensko český hematologický a transfuziologický zjazd**. Bratislava, The Slovak Republic, September 2015.
- Jelínek T, **Hájek R.** Nové perspektivní léky v léčbě mnohočetného myelomu. **XVII. Slovensko český hematologický a transfuziologický zjazd**. Bratislava, The Slovak Republic, September 2015.
- Vladimír Maisnar, Jana Pelcová, Jiří Jarkovský, **Roman Hájek**. AKTUÁLNÍ VÝSTUPY Z REGISTRU MONOKLONÁLNÍCH GAMAPATIÍ CMG. **XVII. Slovensko český hematologický a transfuziologický zjazd**. Bratislava, The Slovak Republic, September 2015.

6/2015 Rakousko

- **Hájek R.** - předsednictví sekce Multiple myeloma: Clinical studies 2. **EHA 2015**, Vienna, Austria, June 2015.
- M.A. Dimopoulos, P. Moreau, A. Palumbo, D. Joshua, L. Pour, **R. Hájek** et al. Carfilzomib and Dexamethasone Improves Progression-Free Survival and Response Rates vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: the Phase 3 Study ENDEAVOR. **EHA 2015**, Vienna, Austria, June 2015.
- Meletios A. Dimopoulos, A. Keith Stewart, S. Vincent Rajkumar, Tamás Masszi, Ivan Špička, Albert Oriol, **Roman Hájek**. Effect of Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma by Line of Therapy: Interim Results From the Phase 3 Study ASPIRE Study. **EHA 2015**, Vienna, Austria, June 2015.

5/2015 Polsko

- **Hájek R.** The Czech Myeloma Group. **10th Anniversary of the Polish Myeloma Group "Multiple Myeloma: present facts and future expectations"**, Lublin, Poland, May 2015.

5/2015 Slovensko

- **Hájek R.** Čo možno očakávať od pomalidomidu. **Myelómové Fórum 2015**. Piešťany, The Slovak Republic, May 2015.

4/2015 Německo

- **Hájek R.** Long term continuous therapy. **5th Heidelberg Myeloma Workshop: Current status and developments in diagnosis and therapy of Multiple Myeloma**. Heidelberg, Germany, April 2015.

4/2015 Velká Británie

- **Hájek R.** - předsednictví sekce Monitoring Multiple Myeloma. **7th International Symposium: Clinical Applications of Free Light Chain and Heavy/Light Chain Analysis**, Edinburgh, Great Britain, April 2015.

1/2015 Polsko

- **Hájek R.** Progress in unravelling the molecular biology of multiple myeloma. **5. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, January 2015.

1 – 12/ 2014

12/2014 Švýcarsko

- **Hájek R.** Aspire data presentation. **Kyprolis after ASH Meeting**. Zurrich, Switzerland, December 2014.

11/2014 Řecko

- **Hájek R.** MYELOMA STEM CELLS. **2nd International Conference on Multiple Myeloma**, Athens, Greece, November 2014.

8/2014 Velké Británie

- **Hájek R.** Waldenström macroglobulinemia in Czech Republic. **ECWM Meeting at 8th International Workshop on WM**, London, England, August 2014.

4/2014 Itálie

- **Hájek R.** - předsednictví sekce Plenary 8: Myeloma Cooperative Trials in Progress. **European Society for Blood and Marrow Transplantation Meeting**, Milan, Italy, April 2014.

4/2014 Německo

- **Hájek R.** Scientific progress, results and exploitation. **OPTATIO - Partner meeting 2014**, Würzburg, Germany, April 2014.

2/2014 Polsko

- **Hajek R.** Perspective combo regimens in near future: focus on proteasome inhibitors and IMiDs in multiple myeloma. Katedra i Klinika Hematologii Collegium Medium UJ, Krakow, Poland, February 2014.

1/2014 Rakousko

- **Hajek R.** MGUS, SMM and MM: Risk factors and clinical implications. **29. TANNHEIMER SYMPOSIUM HÄMATOLOGIE IM FOKUS – MULTIPLES MYELOM**, Tannheim, Austria, January 2014.

1/2014 Polsko

- **Hajek R.** Current Perspectives of SMM Treatment. **4. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, January 2014.

1 – 12/ 201312/2013 USA

- **Hájek R.** - předsednictví sekce Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients, **55th ASH Annual Meeting**, New Orleans, USA, December 2013.

11/2013 Itálie

- **Hájek R.** Markers predicting transitiv of MGUS into myeloma, **The educational Course: “Multiple Myeloma and Related Malignancies, 2nd Edition”**, Bari, Italy, November 2013.

10/2013 Irsko

- **Hájek R.** MLN 9708, **ESH International Conference on Multiple Myeloma**, Dublin, Ireland, October 2013.

4/2013 Japonsko

- Gay F., **Hajek R.**, Di Raimondo F., et al. Cyclophosphamide-Lenalidomide-Dexamethasone vs Autologous Transplant in Newly Diagnosed Myeloma: a Phase 3 Trial., **14th International Myeloma Workshop, IMW 2013**, Kyoto, April 2013.
- Delforge M., Dimopoulos M., Adam Z., **Hajek R.**, Yu Z., Herbein L., Jacques C., Palumbo A. Long-term Safety of Continuous Lenalidomide Therapy in Newly Diagnosed Multiple Myeloma Patients: MM-015 Update. **14th International Myeloma Workshop, IMW 2013**, Kyoto, April 2013.

2/2013 Německo

- **Hájek R.** New data with new agents, **The Multiple Myeloma Debates 2013: Recent Advances in Multiple Myeloma Educational Updates from ASH 2012**, Berlin, Germany, February 2013.

1/2013 Polsko

- **Hájek R.** Clonaltide and its implications for future treatment strategies, **3. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, January 2013.